Breaking News From Pharma & Bio Ingredients
Generex Biotechnology To Develop Small Pox Vaccine
Posted on 2005-02-10 06:00:00
Generex Biotechnology Corporation announced today that its wholly owned subsidiary, Antigen Express, has established collaborations with Emory University and the Imperial College of London to develop a novel smallpox vaccine. The vaccine is based on proprietary Antigen Express technology employing modified peptide antigens to stimulate immunity. The collaboration brings together one of the pre-eminent investigators on vaccinia, Dr. Geoffrey Smith of the Imperial College, and the noted immunologist Dr. Rafi Ahmed of Emory University. Dr. Robert Humphreys, founder of Antigen Express, will coordinate the program at Antigen Express.
Antigen Express has developed proprietary technologies that dramatically enhance the immunogenicity of small fragments from viral or tumor-associated proteins. "This is a particularly attractive strategy in the case of bioterror agents such as smallpox," said Robert Humphreys, founder and Chief Scientific Officer of Antigen Express. "The manufacture of small peptides is trivial compared to whole virus and safety concerns are virtually negligible. We are excited and fortunate to be able to work with such distinguished individuals as Drs. Geoffrey Smith and Rafi Ahmed on this project."
Subscribe via RSS
